BonesLabsBlog
Back to all posts
Uncategorized

PNC-27

PNC-27: A Membranolytic Anti-Cancer Peptide Targeting HDM-2

Research summary. PNC-27 is a synthetic chimeric peptide consisting of an HDM-2 binding domain (corresponding to residues 12–26 of the p53 tumour-suppressor protein) fused to a membrane-penetrating sequence. It was developed at SUNY Downstate Medical Center by Pincus and Michl, originally in the context of HIV research, and has been studied extensively in preclinical cancer models for its reported ability to selectively destroy cancer cells via membranolysis. The proposed selectivity is attributed to differential surface expression of HDM-2 on tumour-cell membranes relative to non-transformed cells.

Molecular profile

  • Composition: HDM-2 binding domain (p53 residues 12–26) + transmembrane-penetrating domain
  • Molecular formula: C₁₈₈H₂₉₃N₅₃O₄₄S
  • Molecular weight: ~4031.7 g/mol
  • Class: Synthetic chimeric anti-cancer peptide; membranolytic agent
  • Synonyms: p53 12–26 fusion peptide; MDM-2/HDM-2-targeting peptide

Mechanism of action

PNC-27's reported mechanism distinguishes it from most p53-MDM-2-axis pharmacology, which typically aims to disrupt nuclear MDM-2-p53 binding to restore p53 transcriptional activity. PNC-27 instead targets HDM-2 (the human MDM-2 homologue) that has been reported on the surface membranes of cancer cells:

  • Surface HDM-2 binding. The HDM-2-binding p53(12–26) domain anchors PNC-27 to surface-localised HDM-2 on transformed cells.
  • Pore formation. The transmembrane-penetrating domain inserts into the lipid bilayer, generating membrane pores.
  • Osmotic lysis. Pore formation disrupts osmotic equilibrium, leading to rapid cell membrane breakdown ("membranolysis") and necrotic cell death.
  • Selectivity claim. Non-transformed cells reportedly do not express HDM-2 at the cell surface to the same extent, providing the basis for the selectivity reported in the originating group's work.

This necrosis-via-membranolysis mechanism is mechanistically distinct from the apoptotic, transcription-restoration mechanism of nuclear MDM-2 inhibitors such as nutlins.

Preclinical research highlights

In vitro tumour-cell killing. PNC-27 has been reported to induce rapid necrotic death across a broad spectrum of cancer cell lines, including pancreatic, breast, melanoma, leukaemia, and several solid-tumour lines. Reported time-to-cell-death is unusually short relative to apoptosis-inducing agents.

Selectivity for transformed cells. The originating group has reported sparing of non-transformed primary cells in co-culture and animal studies, attributed to the absence of substantial surface HDM-2 expression on non-cancerous cells.

Animal-model observations. Rodent xenograft studies have reported tumour regression, with the originating group describing characteristic time-course observations including transient inflammatory-type responses and elevations in lactate dehydrogenase and bilirubin consistent with substantial tumour-cell breakdown.

Mechanistic confirmation. Membrane-fragmentation studies, lipid-bilayer model work, and electron-microscopy observations have been reported in support of the membranolytic mechanism.

Limitations of the evidence base

  • The published PNC-27 literature is concentrated in a relatively small group of investigators, with limited independent replication of the surface-HDM-2 claim by other laboratories.
  • The cell-surface localisation of HDM-2 itself remains a subject of ongoing debate in the broader oncology literature.
  • No completed late-stage human clinical trials have established efficacy or safety in human cancer indications.
  • Reported effects in rodent models have not yet translated into approved therapeutic use.

Current research status

PNC-27 is an investigational research peptide. It is not approved by the FDA for any indication. Research interest is concentrated in mechanistic oncology and in characterisation of surface HDM-2 as a potential tumour-selective target.

For research-supplier contexts, PNC-27 is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

  • PNC-27 is a chimeric peptide combining an HDM-2-binding p53 fragment with a membrane-penetrating sequence.
  • The proposed mechanism is membranolysis driven by binding to surface HDM-2 on transformed cells, distinct from nuclear MDM-2 inhibitors.
  • Reported preclinical effects include rapid necrotic killing of multiple cancer cell lines and tumour regression in rodent xenograft models, with reported sparing of non-transformed cells.
  • The cell-surface HDM-2 mechanism remains debated outside the originating research group.
  • PNC-27 is not an FDA-approved drug.

References

  1. Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR. PNC-27, a chimeric p53/penetratin peptide, kills cancer cells but not normal cells: relation to HDM-2 expression on tumor cell membranes. Int J Cancer. 2006;119(7):1577–1585.
  2. Davitt K, Babcock BD, Fenelus M, Pincus MR. The anti-cancer peptide PNC-27 targets HDM-2 in the cancer cell membrane. Exp Mol Pathol. 2014;96(1):74–79.

This article is provided for educational and research purposes only. PNC-27 is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

PNC-27 | BonesLabs